NNOX: NNOX Q2: revenue +37% but $40.7M AI intangible impairment drives large GAAP loss; cash $31.4M, $8.5M raised post-quarter

AI Summary

Nanox (NNOX) reported Q2 2026 revenue of $4.2M (up 37% y/y, driven by consolidation of Nanox Health IT) but recorded a GAAP net loss of $55.5M after taking a $40.7M impairment on AI-related intangible assets; adjusted EBITDA loss was $11.3M, cash was ~$31.4M at quarter-end and the company raised $8.5M post-quarter. Management highlighted commercial progress — expanded U.S. distribution to ten partners, the first Nanox Imaging Network site began patient scans with some insurer reimbursement, new Nanox.AI reseller and pilot programs, and additional capex deployments — while restructuring Korean operations (67% workforce reduction) to target about $2M in annual savings; a securities class-action was filed and is at an early stage.

Positives

Revenue rose 37% y/y to $4.2M in Q2 2026, driven primarily by consolidation of Nanox Health IT
First Nanox Imaging Network site began patient scans and the company has begun receiving some insurer reimbursement
Raised $8.5M of gross proceeds after the quarter to bolster liquidity

Negatives

Recorded a $40.7M impairment on AI-related intangible assets, reducing their fair value to $1.9M
Cash and cash equivalents declined to ~$31.4M from $60.0M at Dec-31-2025 and company expects to continue raising funds
A class-action securities lawsuit was filed (Steele v. Nano‑X) and remains in early stages